litlas
ログインアカウント作成

Tal Zaks

1998–2024 年に発表

31
論文数
20,568
被引用数
27
h 指数
30
i10 指数

被引用数

Tal Zaks の年別被引用数1969 年: 被引用 1 件1974 年: 被引用 1 件1999 年: 被引用 10 件2000 年: 被引用 25 件2001 年: 被引用 17 件2002 年: 被引用 27 件2003 年: 被引用 14 件2004 年: 被引用 25 件2005 年: 被引用 35 件2006 年: 被引用 35 件2007 年: 被引用 32 件2008 年: 被引用 40 件2009 年: 被引用 47 件2010 年: 被引用 49 件2011 年: 被引用 53 件2012 年: 被引用 47 件2013 年: 被引用 39 件2014 年: 被引用 40 件2015 年: 被引用 34 件2016 年: 被引用 26 件2017 年: 被引用 30 件2018 年: 被引用 41 件2019 年: 被引用 110 件2020 年: 被引用 189 件2021 年: 被引用 2,218 件2022 年: 被引用 1,879 件2023 年: 被引用 1,146 件2024 年: 被引用 1,586 件2025 年: 被引用 1,079 件2026 年: 被引用 36 件1970〜1973 年は被引用が無いため表示していません1975〜1998 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,479 件、この内訳の 27.6%中国: 引用元論文 1,328 件、この内訳の 10.5%イギリス: 引用元論文 733 件、この内訳の 5.8%ドイツ: 引用元論文 549 件、この内訳の 4.3%イタリア: 引用元論文 501 件、この内訳の 4%カナダ: 引用元論文 463 件、この内訳の 3.7%フランス: 引用元論文 327 件、この内訳の 2.6%オーストラリア: 引用元論文 324 件、この内訳の 2.6%日本: 引用元論文 310 件、この内訳の 2.4%スペイン: 引用元論文 291 件、この内訳の 2.3%韓国: 引用元論文 289 件、この内訳の 2.3%インド: 引用元論文 285 件、この内訳の 2.2%
0%27.6%その他 29.7%

機関

分野

  • Medicine54.7%
  • Biochemistry, Genetics and Molecular Biology28.9%
  • Immunology and Microbiology7.9%
  • Social Sciences2%
  • Materials Science1.4%
  • Engineering1.1%
  • その他4%

トピック

  • SARS-CoV-2 and COVID-19 Research14.6%
  • RNA Interference and Gene Delivery8.2%
  • COVID-19 Clinical Research Studies5.4%
  • Immunotherapy and Immune Responses5.2%
  • Vaccine Coverage and Hesitancy3.6%
  • Advanced biosensing and bioanalysis techniques2.9%
  • その他60.1%

共著者

全論文

検索で開く
  1. Lipid nanoparticles for mRNA delivery

    著者: Xucheng Hou, Tal Zaks, Róbert Langer, Yizhou Dong - Nature Reviews Materials 2021 被引用: 3,651

  2. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine

    著者: Lindsey R. Baden, Hana M. El Sahly, Brandon Essink, Karen Kotloff, Sharon Frey, Rick Novak, David Diemert, Stephen A. Spector, Nadine Rouphael, C. Buddy Creech, John McGettigan, Shishir Khetan, Nathan Segall, Joel Solis, Adam Brosz, Carlos Fierro, Howard Schwartz, Kathleen Neuzil, Lawrence Corey, Peter Gilbert, Holly Janes, Dean Follmann, Mary Marovich, John Mascola, Laura Polakowski, Julie Ledgerwood, Barney S. Graham, Hamilton Bennett, Rolando Pajon, Conor Knightly, Brett Leav, Weiping Deng, Honghong Zhou, Shu Han, Melanie Ivarsson, Jacqueline Miller, Tal Zaks - New England Journal of Medicine 2020 被引用: 10,720

  3. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

    著者: Jeffrey S. Weber, Matteo S. Carlino, Adnan Khattak, Tarek Meniawy, George Ansstas, Matthew H. Taylor, Kevin B. Kim, Meredith McKean, Georgina V. Long, Ryan J. Sullivan, Mark B. Faries, Thuy Tran, C. Lance Cowey, Andrew L. Pecora, Montaser Shaheen, Jennifer Segar, Theresa Medina, Victoria Atkinson, Geoffrey T. Gibney, Jason J. Luke, Sajeve Thomas, Elizabeth I. Buchbinder, Jane A Healy, Mo Huang, Manju Morrissey, Igor Feldman, Vasudha Sehgal, Céline Robert-Tissot, Peijie Hou, Lili Zhu, Michelle Brown, Praveen Aanur, Robert Meehan, Tal Zaks - The Lancet 2024 被引用: 739

  4. mRNA vaccine–induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer

    著者: Gal Cafri, Jared J. Gartner, Tal Zaks, Kristen Hopson, Noam Levin, Biman C. Paria, Maria R. Parkhurst, Rami Yossef, Frank J. Lowery, Mohammad Jafferji, Todd D. Prickett, Stephanie L. Goff, Christine T. McGowan, Samantha J. Seitter, Mackenzie L. Shindorf, Anup Y. Parikh, Praveen D. Chatani, Paul F. Robbins, Steven A. Rosenberg - Journal of Clinical Investigation 2020 被引用: 414

  5. Preclinical and Clinical Demonstration of Immunogenicity by mRNA Vaccines against H10N8 and H7N9 Influenza Viruses

    著者: Kapil Bahl, Joe J. Senn, Olga Yuzhakov, Alex Bulychev, Luis A. Brito, Kimberly J. Hassett, Michael E. Laska, Mike Smith, Örn Almarsson, James Thompson, Amilcar Ribeiro, Mike Watson, Tal Zaks, Giuseppe Ciaramella - Molecular Therapy 2017 被引用: 654

  6. mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials

    著者: Robert Feldman, Rainard Fuhr, Igor Smolenov, Amilcar Ribeiro, Lori Panther, Michael Watson, Joseph J. Senn, Mike Smith, Örn Almarsson, Hari Pujar, Michael E. Laska, James D. Thompson, Tal Zaks, Giuseppe Ciaramella - Vaccine 2019 被引用: 463

  7. A phase 1 trial of lipid-encapsulated mRNA encoding a monoclonal antibody with neutralizing activity against Chikungunya virus

    著者: Allison August, Husain Attarwala, Sunny Himansu, Shiva Kalidindi, Sophia Lu, Rolando Pajón, Shu Han, Jean‐Michel Lecerf, Joanne E. Tomassini, Marjie Hard, Leon M. Ptaszek, James E. Crowe, Tal Zaks - Nature Medicine 2021 被引用: 186

  8. A phase 1, randomized, placebo-controlled study to evaluate the safety and immunogenicity of an mRNA-based RSV prefusion F protein vaccine in healthy younger and older adults

    著者: Antonios O. Aliprantis, Christine A. Shaw, Paul Griffin, Nicholas Farinola, Radha Railkar, Xin Cao, Wen Liu, Jeffrey R. Sachs, Christine J. Swenson, Heather Lee, Kara S. Cox, Daniel S. Spellman, Colleen J. Winstead, Igor Smolenov, Eseng Lai, Tal Zaks, Amy S. Espeseth, Lori Panther - Human Vaccines & Immunotherapeutics 2020 被引用: 151

  9. mRNA-encoded, constitutively active STINGV155M is a potent genetic adjuvant of antigen-specific CD8+ T cell response

    著者: Sze-Wah Tse, Kristine McKinney, William H. Walker, Mychael Nguyen, Jared Iacovelli, Clayton Small, Kristen Hopson, Tal Zaks, Eric Yi‐Hsiu Huang - Molecular Therapy 2021 被引用: 102

  10. Safety and Immunogenicity of an mRNA-Based Human Metapneumovirus and Parainfluenza Virus Type 3 Combined Vaccine in Healthy Adults

    著者: Allison August, Christine A. Shaw, Heather Lee, Conor Knightly, Shiva Kalidindia, Laurence Chu, Brandon Essink, William Seger, Tal Zaks, Igor Smolenov, Lori Panther - Open Forum Infectious Diseases 2022 被引用: 83

  11. A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectable solid tumors.

    著者: Howard A. Burris, Manish R. Patel, Daniel C. Cho, Jeffrey Clarke, Martin Gutierrez, Tal Zaks, Joshua P. Frederick, Kristen Hopson, Kinjal Mody, Alverina Binanti-Berube, Céline Robert-Tissot, Bree Goldstein, Ben Breton, Jing Sun, Shan Zhong, Scott K. Pruitt, Karen Keating, Robert Meehan, Justin F. Gainor - Journal of Clinical Oncology 2019 被引用: 144

  12. Abstract CT001: A personalized cancer vaccine, mRNA-4157, combined with pembrolizumab versus pembrolizumab in patients with resected high-risk melanoma: Efficacy and safety results from the randomized, open-label Phase 2 mRNA-4157-P201/Keynote-942 trial

    著者: Adnan Khattak, Matteo S. Carlino, Tarek Meniawy, George Ansstas, Theresa Medina, Matthew H. Taylor, Kevin B. Kim, Meredith McKean, Georgina V. Long, Ryan J. Sullivan, Mark B. Faries, Thuy B. Tran, C. Lance Cowey, Andrew L. Pecora, Jennifer Segar, Victoria Atkinson, Geoffrey T. Gibney, Jason J. Luke, Sajeve Thomas, Elizabeth I. Buchbinder, Peijie Hou, Lili Zhu, Tal Zaks, Michelle Brown, Praveen Aanur, Robert Meehan, Jeffrey S. Weber - Cancer Research 2023 被引用: 49

  13. Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects

    著者: David A. Tuveson, Alice T. Shaw, Nicholas A. Willis, Daniel P. Silver, Erica L. Jackson, Sandy Chang, Kim L. Mercer, Rebecca Grochow, Hanno Hock, Denise Crowley, Sunil R. Hingorani, Tal Zaks, Catrina E. King, Michael A. Jacobetz, Lifu Wang, Roderick T. Bronson, Stuart H. Orkin, Ronald A. DePinho, Tyler Jacks - Cancer Cell 2004 被引用: 816

  14. Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases

    著者: Fawn Qian, Stefan Engst, Toshihiro Yamaguchi, Peiwen Yu, Kwang‐Ai Won, Lillian Mock, Tracy Lou, Jenny Tan, Connie Li, Danny Tam, Julie C. Lougheed, F. Michael Yakes, Frauke Bentzien, Wei Xu, Tal Zaks, Richard Wooster, Joel Greshock, Alison Joly - Cancer Research 2009 被引用: 338

  15. A phase 1, open-label, multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in subjects with resected solid tumors and in combination with pembrolizumab in subjects with unresectable solid tumors (Keynote-603).

    著者: Howard A. Burris, Manish R. Patel, Daniel C. Cho, Jeffrey Clarke, Martin Gutierrez, Tal Zaks, Joshua P. Frederick, Kristen Hopson, Kinjal Mody, Alverina Binanti-Berube, Céline Robert-Tissot, Kristen Cowens, Ben Breton, Shan Zhong, Honghong Zhou, Pamela Cohen, Karen Keating, Robert Meehan, Justin F. Gainor - Journal of Global Oncology 2019 被引用: 25

  16. Cancer therapy using a self-replicating RNA vaccine

    著者: Ying Han, Tal Zaks, Rong‐Fu Wang, Kari R. Irvine, Udai S. Kammula, Francesco M. Marincola, Wolfgang W. Leitner, Nicholas P. Restifo - Nature Medicine 1999 被引用: 324

  17. Author Correction: Lipid nanoparticles for mRNA delivery

    著者: Xucheng Hou, Tal Zaks, Róbert Langer, Yizhou Dong - Nature Reviews Materials 2021 被引用: 33

  18. Immunogenicity and tolerability of personalized mRNA vaccine mRNA-4650 encoding defined neoantigens expressed by the autologous cancer.

    著者: Gal Cafri, Jared J. Gartner, Kristen Hopson, Robert Meehan, Tal Zaks, Paul F. Robbins, Steven A. Rosenberg - Journal of Clinical Oncology 2019 被引用: 26

  19. Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for Cancer

    著者: Amir Massarweh, Noa Eliakim‐Raz, Amos Stemmer, Adva Levy‐Barda, Shlomit Yust‐Katz, Alona Zer, Alexandra Benouaich‐Amiel, Haim Ben‐Zvi, Neta Moskovits, Baruch Brenner, Jihad Bishara, Dafna Yahav, Boaz Tadmor, Tal Zaks, Salomon M. Stemmer - JAMA Oncology 2021 被引用: 291

  20. Randomized Phase II Multicenter Trial of Two Schedules of Lapatinib as First- or Second-Line Monotherapy in Patients with Advanced or Metastatic Non–Small Cell Lung Cancer

    著者: Helen J. Ross, George R. Blumenschein, Joseph Aisner, Nevena Damjanov, Afshin Dowlati, Jennifer Garst, James R. Rigas, Michael Smylie, Habib Hassani, Kimberly E. Allen, Lance Leopold, Tal Zaks, Frances A. Shepherd - Clinical Cancer Research 2010 被引用: 119

  21. INDUCTION OF PROINFLAMMATORY AND CHEMOKINE GENES BY LIPOPOLYSACCHARIDE AND PACLITAXEL (Taxol™) IN MURINE AND HUMAN BREAST CANCER CELL LINES

    著者: Meirav Zaks‐Zilberman, Tal Zaks, Stefanie N. Vogel - Cytokine 2001 被引用: 101

  22. Safety and immunogenicity of a mRNA-based chikungunya vaccine in a phase 1 dose-ranging trial

    著者: Christine A. Shaw, Lori Panther, Allison August, Tal Zaks, Igor Smolenov, Stephan Bart, M. Watson - International Journal of Infectious Diseases 2019 被引用: 32

  23. Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II study

    著者: Bella Kaufman, Maureen Trudeau, Ahmad Awada, Kimberly Blackwell, Thomas Bachelot, Vanessa Salazar, Michelle DeSilvio, Ronald Westlund, Tal Zaks, Neil L. Spector, Stephen Johnston - The Lancet Oncology 2009 被引用: 118

  24. Cancer Cell Lines as Genetic Models of Their Parent Histology: Analyses Based on Array Comparative Genomic Hybridization

    著者: Joel Greshock, Katherine L. Nathanson, Anne‐Marie Martin, Lin Zhang, George Coukos, Barbara Weber, Tal Zaks - Cancer Research 2007 被引用: 82